Questions: Granulomas: Formation and Chronic Inflammation

Question 1

A patient on TNF-α inhibitor therapy for rheumatoid arthritis develops reactivated tuberculosis. Which aspect of granuloma biology best explains this risk?

• A. TNF-α inhibitors impair early macrophage activation, preventing initial mycobacterial containment
• B. Anti-TNF therapy reduces Th2 cell differentiation, allowing opportunistic infections to establish
• C. TNF-α is required to maintain established granuloma integrity, so its inhibition disrupts existing granulomas that contain latent mycobacteria
• D. Anti-TNF drugs are directly toxic to the fibrous capsule surrounding the granuloma

Answer: (C)

TNF-α, secreted abundantly by activated macrophages within granulomas, is essential for granuloma integrity and maintenance — not just initial formation. Established granulomas in latent TB successfully wall off viable mycobacteria, preventing dissemination. When TNF-α is pharmacologically inhibited, this structural maintenance fails: granuloma architecture breaks down, releasing previously contained mycobacteria that can then disseminate. This is why screening for latent TB is required before starting anti-TNF therapy — the drug doesn't cause a new infection, it reactivates a successfully contained old one by dismantling the containment structure.

Question 2

A lung biopsy shows granulomas. Which histological feature most strongly suggests tuberculosis as the cause rather than sarcoidosis?

• A. Presence of multinucleated giant cells within the granuloma
• B. Surrounding rim of CD4+ T lymphocytes
• C. Pink amorphous material at the granuloma center indicating caseating necrosis
• D. Epithelioid macrophage transformation within the collection

Answer: (C)

Caseating necrosis — appearing as pink, cheese-like amorphous material at the granuloma center — is the histological hallmark that most strongly points to tuberculosis (or atypical mycobacteria). This results from macrophage death, toxic complement products, and lysosomal enzyme release at the granuloma core. Non-caseating granulomas (lacking this central necrosis) have a much broader differential including sarcoidosis, fungal infections, Crohn's disease, and berylliosis. Giant cells, lymphocytic rimming, and epithelioid transformation appear in both caseating and non-caseating granulomas — they are features of granulomatous inflammation generally, not TB specifically.

Question 3

Granulomas represent a failure of the immune system — evidence that macrophages have been overwhelmed and can seldom mount an effective defense.

• T. True
• F. False

Answer: False

Granulomas are an adaptive strategy, not a failure. They represent the immune system's purposeful response to persistent antigens it cannot eliminate: containing what it cannot destroy. This is why granulomas require active Th1/IFN-γ signaling to form and maintain — they are not a passive accumulation but an organized, cytokine-sustained structure. The 'failure' framing gets the biology backwards: disrupting granulomas (as TNF-α inhibitors do) causes disease, confirming that granulomas were successfully protecting the host from dissemination.

Question 4

The presence of multinucleated giant cells in a tissue sample is diagnostic of tuberculosis.

• T. True
• F. False

Answer: False

Multinucleated giant cells form when epithelioid macrophages fuse their membranes together, but this process occurs in many types of granulomatous inflammation — including sarcoidosis, fungal infections (Histoplasma, Coccidioides), berylliosis, and foreign body reactions. They are a morphological hallmark of granulomatous inflammation generally, not a specific marker for TB. Additionally, the Common Misconceptions note that not all granulomas even contain giant cells — their presence is not required for the diagnosis of granulomatous inflammation.

Question 5

Why does a granuloma both protect and harm the host simultaneously, and what determines whether the net effect is beneficial?

Model answer: The granuloma protects by walling off the pathogen or irritant, preventing dissemination. It harms by sustaining Th1/macrophage activity that releases cytokines and enzymes damaging surrounding tissue, and by progressive fibrosis that replaces functional parenchyma. The same mechanism that contains the infection degrades the organ hosting it.

Whether the net effect is beneficial depends on where the granuloma forms and how long it persists. A granuloma that successfully contains a mycobacterial infection for decades with minimal tissue destruction is overwhelmingly beneficial. But granulomas in functionally critical tissue — pulmonary granulomas causing progressive fibrosis and restrictive lung disease, hepatic granulomas in schistosomiasis — can cause significant morbidity even while performing their containment function. The key clinical insight is that granulomatous inflammation is protective containment at the cost of local tissue destruction, and the cost-benefit balance is site- and time-dependent.